Biotech entity
Bayer Aktiengesellschaft is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 15 original sources on average, compared with 4.2 for the broader beat in this window. The 6.5 average consequence score is above the beat benchmark of 6.3 in the same window.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Bayer Aktiengesellschaft is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 15 original sources on average, compared with 4.2 for the broader beat in this window. The 6.5 average consequence score is above the beat benchmark of 6.3 in the same window. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Biotech stories that mention Genmab A/S, published between February 18, 2026 and February 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 40 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab A/S. Shared-story counts are live from our verified record — not editorial picks.
Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.
Source: insidermonkey.com · seekingalpha.com
Genmab A/S reported a decline in full-year profits, marking a period of significant financial and clinical divergence across the biotechnology sector. While breakthrough results in depression therapy propelled Compass Pathways, Ocular Therapeutix suffered a sharp decline despite meeting Phase 3 trial endpoints.
Genmab A/S is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
